DNLI vs RXRX: stock comparison and AI forecast
Denali Therapeutics Inc. (DNLI) and Recursion Pharmaceuticals, Inc. (RXRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DNLI Denali Therapeutics Inc.
- Price
- $20.96 +2.7% · 6M
- Market Cap
- $3.15B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
RXRX Recursion Pharmaceuticals, Inc.
- Market Cap
- $2.08B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DNLI is 1.5 times larger than RXRX by market capitalization ($3.15B against $2.08B).
- RXRX turns -879.4% of its revenue into net income, against -1768.6% for DNLI.
- DNLI carries 0.36 times debt per unit of equity, against 0.35 times for RXRX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DNLI | RXRX |
|---|---|---|
| Market Cap | $3.15B | $2.08B |
| P/B Ratio | 3.40x | 2.29x |
| EPS | $-1.82 | $-1.30 |
| Book Value/Share | $5.80 | $1.69 |
| Revenue/Share | – | $0.10 |
| FCF/Share | $-2.82 | $-0.58 |
Profitability & Margins
| Metric | DNLI | RXRX |
|---|---|---|
| ROE | -33.9% | -52.5% |
| ROA | -25.0% | -38.9% |
| ROIC | -45.8% | -45.0% |
| Operating Margin | -2992.5% | -915.1% |
| Net Margin | -1768.6% | -879.4% |
| EBT Margin | -2992.5% | -887.8% |
| Tax Rate | – | 0.9% |
Financial Health
| Metric | DNLI | RXRX |
|---|---|---|
| Current Ratio | 6.21x | 5.01x |
| Quick Ratio | 5.94x | – |
| D/E Ratio | 0.36x | 0.35x |
| Financial Leverage | 1.36x | 1.35x |
| Interest Coverage | – | -4817.0x |
| Working Capital | $496M | $493M |
Cash Flow
| Metric | DNLI | RXRX |
|---|---|---|
| Operating Cash Flow | -$444M | -$311M |
| Free Cash Flow | -$450M | -$312M |
| Capital Spending | -$6M | -$2M |
| FCF/Sales | – | -577.7% |
| CapEx/Sales | – | 3.6% |
Operational Efficiency
| Metric | DNLI | RXRX |
|---|---|---|
| Asset Turnover | – | 0.04x |
| Fixed Assets Turnover | – | 0.6x |
| Payables Period | – | 124 days |
Income Statement
| Metric | DNLI | RXRX |
|---|---|---|
| Total Revenue | – | $54M |
| Operating Income | -$532M | -$495M |
| Net Income | -$314M | -$476M |
| R&D Expense | $405M | $373M |
| Cost of Goods Sold | – | $48M |
Dividend & Shareholder Information
| Metric | DNLI | RXRX |
|---|---|---|
| Shares Outstanding | 160M | 535M |
DNLI vs RXRX: stock comparison and AI forecast
Which is bigger, DNLI or RXRX?
DNLI is 1.5 times larger than RXRX by market capitalization ($3.15B against $2.08B).
Which one does Intratio's AI model rank higher, DNLI or RXRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.